Search Results
Your search for can matches 13758 pages
Showing 13401 - 13450Study Shows 20% of Women With Ovarian Cancer Have Inherited Genetic Mutations That Increase Risk of Disease
A large-scale genetic analysis of women with ovarian cancer with no known family histories of breast or ovarian cancer has found that one-fifth of them had inherited alterations in genes known to be associated with these cancers. The findings could lead to the development of better screening...
Intensity-Modulated Radiation Therapy Improves Survival in Patients With Head and Neck Cancer
Patients with cancers of the head and neck who received intensity-modulated radiation therapy experienced improved outcomes, as well as reduced toxicities, compared to patients receiving conventional radiation therapy, according to findings published online in Cancer by Beadle et al. The study is...
Model of Individualized Estimates Shows Risk of Overdiagnosis in Screening-Detected Prostate Cancers Varies Widely by Age, PSA, and Gleason Score
It is estimated that overdiagnosis occurs in approximately 20% to 40% of prostate cancers detected at screening in U.S. men aged 50 to 84 years, with the likelihood of overdiagnosis varying widely according to patient age and tumor characteristics. In a study reported in the Journal of the...
MicroRNA Test Reduces False-Positive CT Screening Rate for Lung Cancer
Although recent data indicate that low-dose computed tomography (CT) reduces lung cancer mortality in high-risk patients, high false-positive rates, costs, and the potential for harm point out the need for biomarkers that can improve risk assessment. In a study reported in the Journal of Clinical...
Multiple Myeloma Study Shows Widespread Genetic Heterogeneity
A detailed study of tissue samples from more than 200 patients with multiple myeloma has found that an individual patient’s tumor can harbor populations of cancer cells equipped with different mutations. The result could have therapeutic ramifications for future patients, according to study...
Nurse- and Gastroenterologist-Led Algorithm-Based Management Improve GI Symptoms After Pelvic Radiotherapy
In the ORBIT trial, reported in The Lancet, Andreyev et al compared outcomes with usual care, gastroenterologist-led algorithm-based management, and nurse-led algorithm-based management for patients with chronic gastrointestinal symptoms following pelvic radiotherapy for cancer. The findings...
Web-Based Self-Care Support and Communication Coaching Program Reduces Symptom Distress in Cancer Patients
In the ESRA-CII trial reported in the Journal of Clinical Oncology by Berry et al, patient use of a Web-based self-care program featuring tailored education and communication coaching resulted in significantly reduced symptom distress compared with symptom/quality-of-life tracking alone in patients ...
Half of Patients With Stage I Pediatric Malignant Ovarian Germ Cell Tumors Can Be Spared Chemotherapy After Initial Surgery With Surveillance Strategy
In a Children’s Oncology Group study (AGCT0132) reported in the Journal of Clinical Oncology, Billmire et al found that overall survival can be preserved in patients with stage I pediatric malignant ovarian germ cell tumor with a strategy of initial surveillance after surgical resection....
FDA Approves Combination Therapy for Unresectable or Metastatic Melanoma With BRAF V600E/K Mutations
The U.S. Food and Drug Administration (FDA) has approved trametinib (Mekinist) for use in combination with dabrafenib (Tafinlar) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutations. These mutations must be detected by an FDA-approved...
Major Decline in Lung Cancer Reported
“Eliminating tobacco use is the most important thing we can do to prevent lung and other cancers, as well as the many other diseases its use causes. Today’s news confirms that we are making progress. However, the global health challenges from tobacco are still growing. “This new...
Preclinical Study Suggests E-Cigarettes May Contribute to Lung Cancer in High-Risk Individuals
A study of human bronchial epithelial cells carrying mutations in the TP53 and KRAS genes has found that e-cigarette vapors enhanced the cells’ cancerous behaviors. The study suggests that e-cigarette exposure may contribute to lung cancer in individuals at high risk for the disease. The...
Recurrent Ovarian Cancers Respond to Cancer Vaccine After ‘Reprogramming’ With Decitabine
Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide a new treatment option for patients with the disease, according to a...
Oral Insulin Sensitizers Associated With Decreased Cancer Risk in Women With Type 2 Diabetes
According to the findings of a meta-analysis by Sun et al published in Diabetes, Obesity, and Metabolism, patients with type 2 diabetes mellitus who are on certain therapies, such as insulin secretagogues, may be at higher risk for cancer. This increased risk was seen more frequently in women, and...
Imiquimod 5% Cream Inferior to Surgical Excision in Nodular and Superficial Basal Cell Carcinoma
In a noninferiority trial (SINS) reported in The Lancet Oncology, Bath-Hextall et al compared imiquimod 5% cream vs surgical excision for nodular and superficial basal cell carcinomas. Imiquimod cream was found to be inferior to surgical excision, but it may have a role in treatment of low-risk...
Sustained Complete Responses With Novel Immunotherapy in Lymphoma
Approximately 40% of patients with Hodgkin or non-Hodgkin lymphoma have tumor cells that express the type II latency Epstein-Barr virus (EBV) antigens latent membrane protein 1 (LMP1) and LMP2. T cells specific for these antigens are present in low levels and may be rendered nonreactive by the...
Low-Dose CT Screening May Result in Overdiagnosis of Lung Cancer
In a study reported in JAMA Internal Medicine, Patz et al of the NLST Overdiagnosis Manuscript Writing Team estimated the magnitude of overdiagnosis using low-dose computed tomography (CT) screening for lung cancer in the National Lung Screening Trial (NLST). They estimated that more than 18% of...
Younger Women With Younger Children Less Likely to Receive Radiation Therapy After Breast-Conserving Surgery for Breast Cancer
In a study reported in the Journal of the National Cancer Institute, Pan et al assessed factors associated with noncompliance with recommended radiation therapy following breast-conserving surgery for breast cancer. A primary factor in underuse of radiation therapy was younger patients having...
Dasatinib/Letrozole Drug Combination Delays Disease Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Adding dasatinib (Sprycel) to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor–positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented at the 2013 San Antonio Breast...
Novel BRAF Fusions Identified in 'Pan-Negative' Melanomas
A study by Sosman et al has identified two novel BRAF fusions in melanomas previously considered to be negative for molecular targets. In addition, these “pan-negative” melanomas were found to be sensitive to MEK inhibitors. According to the study, BRAF fusions define a new molecular...
CALGB 40603 Trial Supports Adding Carboplatin to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
The addition of carboplatin to a neoadjuvant regimen significantly increased the rate of pathologic complete response in patients with triple-negative breast cancer. The results from the CALGB/Alliance 40603 study were reported at the 2013 San Antonio Breast Cancer Symposium (Abstract S5-01)....
Adjuvant Paclitaxel/Trastuzumab Tolerable, Benefits Women With Stage I HER2-Positive, Node-Negative Breast Cancer
There may be a benefit for treating small HER2-positive tumors and this can be done with little toxicity, according to a multicenter study presented at the 2013 San Antonio Breast Cancer Symposium (Abstract S1-04). Previous studies of chemotherapy plus anti-HER2 treatment for node-negative...
Addition of Bevacizumab Fails to Improve Invasive Disease-Free Survival vs Adjuvant Chemotherapy/Trastuzumab Alone in HER2-Positive Breast Cancer
Bevacizumab (Avastin) failed to extend invasive disease–free survival when added to trastuzumab (Herceptin)-directed adjuvant chemotherapy in patients with HER2-positive breast cancer in the phase III BETH trial. Although not specifically designed to answer this question, BETH also...
High Levels of Immune Cells in Tumors May Identify Breast Cancer Patients Most Likely to Benefit From Trastuzumab
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab (Herceptin), according to results presented today at the 2013 San Antonio Breast Cancer Symposium (Abstract S1-05)....
Ibrutinib/Rituximab Combination Leads to High Response Rate Among Patients With CLL
Nearly all of the patients with high-risk chronic lymphocytic leukemia (CLL) in a phase II clinical trial responded to treatment with the targeted therapy ibrutinib (Imbruvica) and the antibody rituximab (Rituxan), researchers reported at the 55th American Society of Hematology (ASH) Annual Meeting ...
Biologic Doublet a Potential Front-Line Treatment in Mantle Cell Lymphoma
A high proportion of mantle cell lymphoma patients may achieve an objective and durable response to treatment with an initial chemotherapy-free regimen, according to Jia Ruan, MD, PhD, of Weill Cornell Medical College, New York, who presented the results of a multicenter phase II study at the 55th...
Biologic Mechanism May be Linked to Racial Disparities in Prostate Cancer
In the United States, African American men are 1.6 times more likely to develop prostate cancer and more than 2.5 times as likely to die from the disease than non-Hispanic white men, according to the U.S. Department of Health & Human Services. A study by David P. Turner, PhD, Assistant...
Long-Term Symptoms Beyond 10 Years Experienced by Prostate Cancer Survivors
Years after receiving treatment, many patients who survive prostate cancer continue to experience treatment-related symptoms, according to the findings of a study by Darwish-Yassine et al published in the Journal of Cancer Survivorship. These findings highlight the need for improvements in survivor ...
Obinutuzumab/Chlorambucil Superior to Rituximab/Chlorambucil as First-Line Treatment for Older CLL Patients With Comorbidities
Obinutuzumab (Gazyva) plus chlorambucil (Leukeran) was superior to rituximab (Rituximab) plus chlorambucil as first-line therapy in older chronic lymphocytic leukemia (CLL) patients with comorbidities, with an acceptable safety profile, according to final results of the phase III CLL11 trial....
Successful Chimeric Antigen Receptor–Expressing T-Cell Treatment Reported in Advanced Lymphomas
Development of autologous genetically engineered anti-CD19 chimeric antigen receptor (CAR)-expressing T cells holds promise in the treatment of hematologic malignancies. CAR T cells are being studied in adult and pediatric acute lymphocytic leukemias and in chronic lymphocytic leukemia, and...
Graft Manipulation Improves HLA-Haploidentical Hematopoietic Stem Cell Transplant Outcomes
T-cell–depleted HLA-haploidentical hematopoietic stem cell transplantation can be made more efficacious and safer through the removal of alpha/beta-positive T cells and CD19-positive B cells from the graft, an approach pioneered by Italian investigators who reported results at the 55th...
Higher Levels of HSET Linked to More Aggressive Breast Cancers and Worse Outcomes in African American Women
Data from a study by Ritu Aneja, PhD, Associate Professor in the Department of Biology at Georgia State University in Atlanta, and colleagues indicate that overexpression of the protein HSET is a valuable prognostic biomarker in African American women with breast cancer, but not in Caucasian...
Grade 3 Endometrioid Carcinoma With PIK3CA Mutation Linked to Unfavorable Outcome
The presence of PIK3CA missense mutation appears to be associated with shorter disease-specific survival in grade 3 endometrioid but not serous endometrial carcinoma, according to a study in Gynecologic Oncology. Although McIntyre et al found this type of mutation across all histologic types of...
Hypercholesterolemia May Drive the Growth of Breast Cancer
High levels of the cholesterol metabolite 27-hydroxycholesterol seem to function like estrogen and may independently drive the growth of breast cancer, according to the findings of a preclinical study by Nelson et al published in Science. They also found a possible connection between...
Nurse Navigators Improve Patient-Reported Quality of Care in Early Cancer Care
In a study reported in the Journal of Clinical Oncology, Wagner et al assessed whether a nurse navigator intervention improved quality of life or patient experience with care in patients who recently received a diagnosis of breast, colorectal, or lung cancer. Although no differences in...
Disease-Free Survival Is Acceptable Surrogate for Overall Survival in Trials of Adjuvant Chemotherapy for Gastric Cancers
Disease-free survival is an acceptable surrogate for overall survival in trials of cytotoxic agents for gastric cancer in the adjuvant setting, the GASTRIC group concluded after conducting a meta-analysis of data from 3,288 individual patients enrolled in 14 randomized clinical trials. The trials...
U.S. Preventive Services Task Force Issues Final Recommendations on Screening for Oral Cancer
The U.S. Preventive Services Task Force (USPSTF) today released its final recommendation statement on screening for oral cancer in adults without signs or symptoms of oral cancer who are seen by primary care providers. This recommendation focuses on primary care professionals and is not a...
Thyroid Ultrasound Strategy Identifies Low-Risk Patients Who Can Defer Biopsy
In a study reported in JAMA Internal Medicine, Smith-Bindman et al evaluated the ability of ultrasound imaging characteristics to determine risk of thyroid cancer associated with thyroid nodules. They found that a strategy of using two abnormal nodule characteristics as an indication for biopsy...
FDA Approves Sorafenib to Treat Late-Stage Differentiated Thyroid Cancer
The U.S. Food and Drug Administration today expanded the approved uses of sorafenib (Nexavar) to treat late-stage differentiated thyroid cancer. The new indication is for patients with locally recurrent or metastatic, progressive differentiated thyroid cancer that no longer responds to radioactive...
Study Finds Possible Link Between Allergies and Increased Risk of Hematologic Cancers in Women
A team of researchers looking into the interplay of the immune system and cancer have found a link between a history of airborne allergies—in particular to plants, grass, and trees—with risk of blood cancers in women. The same association was not found in men, suggesting a possible...
STAT3 Activation Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP
In a study reported in the Journal of Clinical Oncology, Xin Huang, PhD, of the National Clinical Research Center of Cancer in Tianjin, and colleagues investigated whether STAT3 activation can identify patients with diffuse large B-cell lymphoma treated with R-CHOP (rituximab [Rituxan] plus...
Prognostic Model Predicts Metastatic Castration-Resistant Prostate Cancer Survival in Second-Line Chemotherapy After Docetaxel
In a study reported in the Journal of the National Cancer Institute, Susan Halabi, MD, of Duke University Medical Center, and colleagues developed and validated a prognostic model predicting prostate cancer survival in patients receiving second-line chemotherapy for castration-resistant...
No Benefit From Adding Cetuximab to Pemetrexed in Recurrent/Progressive NSCLC After Platinum-Based Therapy
In a phase III trial reported in The Lancet Oncology, Edward S. Kim, MD, of Levine Cancer Institute, Carolinas HealthCare System, and colleagues investigated whether the addition of cetuximab (Erbitux) to pemetrexed (Alimta) improved progression-free survival in patients with recurrent or...
Prognostic Score Predicts Overall Survival in Older Patients With Hodgkin Lymphoma by Second-Line Treatment Strategy
In a study reported in the Journal of Clinical Oncology, Boris Böll, MD, of University Hospital Cologne, and colleagues analyzed second-line treatment and survival in older patients with relapsed/refractory Hodgkin lymphoma in German Hodgkin Study Group first-line studies. Use of a...
Assay-Sensitive Treatment Improves Outcomes in Recurrent Ovarian Cancer
The use of assay-sensitive treatment significantly improved both progression-free survival and overall survival compared with nonsensitive treatment in women with recurrent ovarian cancer, according to the results of a prospective clinical trial reported in Gynecologic Oncology. Thomas Rutherford,...
New Mutation Found in the Estrogen Receptor May Cause Resistance to Breast Cancer Treatment
Most patients with estrogen receptor–positive metastatic breast cancer who initially respond to endocrine treatments will eventually develop resistance to the therapies. A study by Ido Wolf, MD, Head of the Oncology Department at the Tel Aviv Sourasky Medical Center in Israel, and colleagues...
Vemurafenib Produces Rapid Responses in Hairy Cell Leukemia
Preliminary results of an ongoing clinical trial suggest that the BRAF inhibitor vemurafenib (Zelboraf)—indicated for the treatment of metastatic melanoma with BRAF V600E mutation—may have an important role in the treatment of hairy cell leukemia. The cornerstone of therapy for this...
FDA Approves Transducer Array Layout System for Use in Patients With Recurrent Glioblastoma Multiforme
Novocure announced today that it has received U.S. Food and Drug Administration (FDA) approval for its NovoTAL (Transducer Array Layout) System through a Premarket Approval supplement. The NovoTAL System allows certified physicians to use the individual magnetic resonance imaging (MRI) data of...
Most Gastroenterologists and Endoscopy Nurses Prefer Propofol Over Moderate Sedation in Screening Colonoscopies, but Would Pay Little Extra for It
Propofol is increasingly being used for sedation in screening colonoscopies in low-risk patients. In the United States, propofol can be administered only by an anesthesiologist, which can raise the cost of the procedure by $600 to $2,000. In a study reported in a research letter in JAMA Internal...
Measuring Hormone Levels Could Improve Risk Assessment for Breast Cancer
The inclusion of multiple hormones—rather than just adding one or two individually—in breast cancer risk prediction models may improve prediction of the disease and could help better identify women who would benefit from chemoprevention, according to a study by Shelley S. Tworoger, PhD, ...
Sale of Ponatinib Suspended Due to Risk of Life-Threatening Blood Clots
The U.S. Food and Drug Administration (FDA) has asked the manufacturer of the tyrosine kinase inhibitor ponatinib (Iclusig) to suspend marketing and sales of the drug because of the risk of life-threatening blood clots and severe narrowing of blood vessels. Ariad Pharmaceuticals has agreed to...
